HP
PVLA

Hound Partners’s Palvella Therapeutics PVLA Stock Holding History

Hound Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,250
Closed -$266K – 35
2018
Q4 		$266K Buy
+1,250
New +$388K 0.01% 28

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Hound Partners's PVLA Position: Q1 2019 in Review

Hound Partners sold out of Palvella Therapeutics (PVLA) in Q1 2019, closing a stake of 1,250 shares — an estimated $266K sold.

Hound Partners first reported a position in PVLA in Q4 2018 and held it in 1 quarter. The position peaked at $266K in Q4 2018. 92 funds tracked by Wall St. Rank hold PVLA as of Q1 2019.

  • Hound Partners reported no remaining Palvella Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Hound Partners sold 1,250 Palvella Therapeutics shares in Q1 2019, an estimated $266K.
  • Hound Partners first reported a position in Palvella Therapeutics in Q4 2018 and held it in 1 quarter.
  • Hound Partners's Palvella Therapeutics position peaked at $266K in Q4 2018.
  • 92 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2019.

Based on Hound Partners's 13F filing for Q1 2019, filed 15 May 2019.